Item no. |
Z02963-50 |
Manufacturer |
GenScript
|
Amount |
50ug |
Category |
|
Type |
Proteins |
Format |
Sterile Filtered White lyophilized (freeze-dried) powder. |
Specific against |
other |
Purity |
>97% by SDS-PAGE and HPLC analyses. |
Sequence |
VIGGDECDIN EHPFLAFMYY SPRYFCGMTL INQEWVLTAA HCNRRFMRIHLGKHAGSVAN YDEVVRYPKE KFICPNKKKN VITDKDIMLI RLDRPVKNSEHIAPLSLPSN PPSVGSVCRI MGWGAITTSE DTYPDVPHCA NINLFNNTVC REAYNGLPAK TLCAGVLQGG IDTCGGDSGG PLICNGQFQG ILSWGSDPCA EPRKPAFYTK VFDYLPWIQS IIAGNKTATC P |
ECLASS 10.1 |
32160409 |
ECLASS 11.0 |
32160409 |
UNSPSC |
12352202 |
Alias |
protein/Z02963_50-Batroxobin_BX_SVTLE_Reptile, Batroxobin is a serine protease derived from the venom of Bothrops atrox. This thrombin-like proteolytic enzyme splits the 16 Arg-17 Gly bond in the A (alpha)-chain of fibrinogen, releasing fibrinopeptide A and leading to the clot formation through aggregation of formed of fibrin I monomer or Des-AA-monomer. In contrast to other anti-coagulants, it does not affect the functions of platelets. Hence, Batroxobin is used to determine fibrinogen in plasma, to measure a 'batroxobin clotting time' as a heparin-insensitive parallel to the thrombin time, to investigate dysfibrinogenemia, and to test the contractile system of platelets.</td></tr><tr><th>M.W.</th><td colspan="7"> A single, glycosylated, polypeptide chain containing 231 amino acids, and having a molecular mass of approximately 28,000ca.33,000.</td></tr><tr><th>Purity</th><td colspan="7"> >97% by SDS-PAGE and HPLC analyses.</td></tr><tr><th>Endotoxin Level</th><td colspan="7"> Less than 0.5EU/mg of rRpBX/SVTLE as determined by LAL method.</td></tr><tr><th>Specific Activity</th><td colspan="7"> Fully biologically active when compared to standard. The biologically activity of rRpBX is no less than 500KU/mg (Klobusitzky Unit). One KU is defined as the amount of enzyme which coagulates standard human plasma incubated at 37 C in vitro within 60+/-20 seconds.</td></tr><tr><th>Storage</th><td colspan="7"> This lyophilized preparation is stable at 2-8C, but should be kept at -20C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20C to -70C. Avoid repeated freeze/thaw cycles. </td></tr><tr><th>Formulation</th><td colspan="7"> Lyophilized from a 0.2um filtered concentrated sodium acetate buffer solution.</td></tr><tr><th>Reconstitution</th><td colspan="7"> We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at <=-20C. Further dilutions should be made in appropriate buffered solutions.</td></tr><tr><th>Physical Appearance</th><td colspan="7"> Sterile Filtered White lyophilized (freeze-dried) powder.</td></tr><tr><th>Sequence</th><td colspan="7"> VIGGDECDIN EHPFLAFMYY SPRYFCGMTL INQEWVLTAA HCNRRFMRIHLGKHAGSVAN YDEVVRYPKE KFICPNKKKN VITDKDIMLI RLDRPVKNSEHIAPLSLPSN PPSVGSVCRI MGWGAITTSE DTYPDVPHCA NINLFNNTVC REAYNGLPAK TLCAGVLQGG IDTCGGDSGG PLICNGQFQG ILSWGSDPCA EPRKPAFYTK VFDYLPWIQS IIAGNKTATC P</td></tr> |
Similar products |
Batroxobin |
Available |
|
Specificity |
Fully biologically active when compared to standard. The biologically activity of rRpBX is no less than 500KU/mg (Klobusitzky Unit). One KU is defined as the amount of enzyme which coagulates standard human plasma incubated at 37 C in vitro within 60+/-20 |
Specificity |
Fully biologically active when compared to standard. The biologically activity of rRpBX is no less than 500KU/mg (Klobusitzky Unit). One KU is defined as the amount of enzyme which coagulates standard human plasma incubated at 37 C in vitro within 60+/-20 seconds. |
Description |
Batroxobin is a serine protease derived from the venom of Bothrops atrox. This thrombin-like proteolytic enzyme splits the 16 Arg-17 Gly bond in the A (alpha)-chain of fibrinogen, releasing fibrinopeptide A and leading to the clot formation through aggregation of formed of fibrin I monomer or Des-AA-monomer. In contrast to other anti-coagulants, it does not affect the functions of platelets. Hence, Batroxobin is used to determine fibrinogen in plasma, to measure a 'batroxobin clotting time' as a heparin-insensitive parallel to the thrombin time, to investigate dysfibrinogenemia, and to test the contractile system of platelets. |
Endotoxin Level |
Less than 0.5EU/mg of rRpBX/SVTLE as determined by LAL method. |
Formulation |
Lyophilized from a 0.2um filtered concentrated sodium acetate buffer solution. |
M.W. |
A single, glycosylated, polypeptide chain containing 231 amino acids, and having a molecular mass of approximately 28, 000ca.33, 000. |
Product Line |
Others |
Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at <=-20C. Further dilutions should be made in appropriate buffered solutions. |
Storage |
This lyophilized preparation is stable at 2-8C, but should be kept at -20C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20C to -70C. Avoid repeated freeze/thaw cycles. |
Product Origin |
USA |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.